Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Nvidia Introduces ‘Ising’ AI Models to Improve Quantum Error Correction and Scalability
Nvidia has announced a new set of open-source artificial intelligence models, termed “Ising,” aimed at addressing persistent technical challenges in quantum computing. Quantum systems, while powerful in theory, face practical limitations due...





Discussion about this post